MIP 1 beta; Secreted protein G 26; ACT 2; ACT-2; ACT2; AT744.1; AT744.2; C C motif chemokine 4; C C motif chemokine 4 like; C C motif chemokine ligand 4 like 1; C C motif chemokine ligand 4 like 2; CC chemokine ligand 4; CC chemokine ligand 4L1; CC chemokine ligand 4L1d2; CC chemokine ligand 4L2; CCL4; CCL4_HUMAN; ccl4l 1; CCL4L; CCL4L1; Chemokine (C C motif) ligand 4; Chemokine (C C motif) ligand 4 like 1; Chemokine (C C motif) ligand 4 like 1, telomeric; Chemokine (C C motif) ligand 4 like 2; Chemokine CC Motif Ligand 4; G 26; G 26 T lymphocyte secreted protein; G-26 T-lymphocyte-secreted protein; HC21; Immune activation 2; LAG 1; LAG-1; LAG1; Lymphocyte activation gene 1; Lymphocyte activation gene 1 protein; Macrophage inflammatory protein 1 beta; Macrophage inflammatory protein 1-beta; Macrophage inflammatory protein 1b2; MGC104418; MGC126025; MGC126026; MIP-1-beta; MIP-1-beta(1-69); MIP-1-beta(3-69); MIP1 beta; MIP1B; MIP1B1; Monocyte adherence induced protein 5 alpha; PAT 744; Protein H400; SCYA2; SCYA4; SCYA4L; SCYA4L1; SCYA4L2; SCYQ4L2; Secreted protein G 26; Secreted protein G26; SIS gamma; SIS-gamma; Small inducible cytokine A4 (homologous to mouse Mip 1b); Small inducible cytokine A4; small inducible cytokine A4-like; Small-inducible cytokine A4; T cell activation protein 2; T-cell activation protein 2

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

CCL4 antibody detects endogenous levels of total CCL4

The antiserum was purified by peptide affinity chromatography using SulfoLink Coupling Resin.

Liquid
Phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

1mg/ml (lot specific)

Store at -20 degree C. Stable for 12 months from date of receipt.

Manufactured in an ISO 9001:2015 Certified Laboratory.

Manufactured in a lab with traceable raw materials manufactured on site. Coordinated product portfolio of antibodies, pairs, conjugates, recombinant proteins, and immunoassay materials available, please inquire.

Small volumes of anti-CCL4 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Description: Chemokines are members of a superfamily of small inducible, secreted, pro-inflammatory cytokines. Members of the chemokine family exhibit 20 to 50% homology in their predicted amino acid sequences and are divided into four subfamilies. In C-C (or b) subfamily, the first two cysteines are adjacent. C-C chemokines are chemoattractants and activators for monocytes and T cells. C-C subfamily members include macrophage inflammatory protein (MIP)-1, MIP-1, MIP-2, MIP-3, MIP-3, MIP-4, HCC-1, MIP-5 (or HCC-2), RANTES, MCP-1/2/3 (and the murine homologs JE and MARC), I-309, murine C10 and TCA3. Research has shown that MIP-1?? is more selective than MIP-1, primarily attracting CD4+ T lymphocytes, with a preference for T cells of the naive phenotype. MIP-1 is a more potent lymphocyte chemoattractant than MIP-1?? and exhibits a broader range of chemoattractant specificities. It has been suggested that CD8+ T lymphocytes are involved in the control of HIV infection in vivo by the release of HIV-suppressive factors (HIV-SF). MIP-1 has been identified as one of the major HIV-SFs produced by CD8+ T cells, along with MIP-1 and RANTES. Recombinant human MIP-1 acts as an inhibitor of different strains of HIV-1, HIV-2 and SIV infection in a dose-dependent manner.
Function: Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B.
Subunit Structure: Homodimer and heterodimer of MIP-1-alpha(4-69) and MIP-1-beta(3-69).
Post-translational Modifications: N-terminal processed form MIP-1-beta(3-69) is produced by proteolytic cleavage after secretion from peripheral blood lymphocytes.
Similarity: Belongs to the intercrine beta (chemokine CC) family.

Western Blot (WB), Immunohistochemistry (IHC), ELISA (EIA)

WB: 1:500-1:2000
IHC: 1:50-1:200

MBS9607201 at 1/100 staining Human Melanoma tissue by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the antibody for 1.5 hours at 22 degree C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.

Western blot analysis of extracts of SGC7901, using CCL4 antibody. The lane on the left is treated with the antigen-specific peptide.

Observed: 10 kDa
Predicted: 11 kDa

C-C motif chemokine ligand 4

C-C motif chemokine 4

C-C motif chemokine 4

LAG1; MIP1B; SCYA4; LAG-1; MIP-1-beta; ACT-2??[Similar Products]

The protein encoded by this gene is a mitogen-inducible monokine and is one of the major HIV-suppressive factors produced by CD8+ T-cells. The encoded protein is secreted and has chemokinetic and inflammatory functions. [provided by RefSeq, Dec 2012]

Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.